C Gordon, MB Amissah-Arthur, M Gayed… - …, 2018 - academic.oup.com
Caroline Gordon1, 2, 3, Maame-Boatemaa Amissah-Arthur1, Mary Gayed1, 3, Sue Brown4, Ian N. Bruce5, 6, David D'Cruz7, Benjamin Empson8, Bridget Griffiths9, David Jayne10, 11 …
Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic …
M Shipa, A Embleton-Thirsk, M Parvaz… - Annals of internal …, 2021 - acpjournals.org
Background: B-cell depletion with rituximab is commonly used for patients with systemic lupus erythematosus (SLE) that is refractory to conventional therapy, but it yields variable …
JG Hanly, AG O'Keeffe, L Su, MB Urowitz… - …, 2016 - academic.oup.com
Objective. To determine nephritis outcomes in a prospective multi-ethnic/racial SLE inception cohort. Methods. Patients in the Systemic Lupus International Collaborating Clinics …
RF Van Vollenhoven, M Mosca, G Bertsias… - Annals of the …, 2014 - ard.bmj.com
The principle of treating-to-target has been successfully applied to many diseases outside rheumatology and more recently to rheumatoid arthritis. Identifying appropriate therapeutic …
BH Hahn, MA Mcmahon, A Wilkinson… - Arthritis care & …, 2012 - Wiley Online Library
In the US, approximately 35% of adults with systemic lupus erythematosus (SLE) have clinical evidence of nephritis at the time of diagnosis, with an estimated total of 50–60 …
J Haanen, MS Ernstoff, Y Wang, AM Menzies… - Annals of oncology, 2020 - Elsevier
Highlights•Solid organ transplantation (SOT) patients or patients with active ADs have been largely excluded from ICIs clinical trials because of the risk of allograft rejection or severe …
BH Rovin, R Furie, K Latinis, RJ Looney… - Arthritis & …, 2012 - Wiley Online Library
Objective To evaluate the efficacy and safety of rituximab in a randomized, double‐blind, placebo‐controlled phase III trial in patients with lupus nephritis treated concomitantly with …
CC Mok, YKO Teng, R Saxena, Y Tanaka - Nature Reviews …, 2023 - nature.com
Despite the continuing development of immunomodulatory agents and supportive care, the prognosis associated with lupus nephritis (LN) has not improved substantially in the past …